LIPOSYN III 10%
Clinical safety rating: caution
Comprehensive clinical and safety monograph for LIPOSYN III 10% (LIPOSYN III 10%).
Liposyn III 10% is an intravenous fat emulsion that provides essential fatty acids (linoleic and linolenic acids) and a source of calories. The triglycerides are hydrolyzed by lipoprotein lipase to free fatty acids and glycerol, which are then utilized for energy production or stored. The emulsion particles are metabolized similarly to endogenous chylomicrons.
| Metabolism | Hydrolyzed by lipoprotein lipase in peripheral tissues, yielding free fatty acids and glycerol. Free fatty acids undergo beta-oxidation in mitochondria for energy or re-esterification into triglycerides. Glycerol is metabolized in the liver via glycolysis or gluconeogenesis. |
| Excretion | Lipids are metabolized via hydrolysis by lipoprotein lipase into free fatty acids and glycerol. Free fatty acids undergo beta-oxidation or re-esterification. Elimination of CO2 via lungs; less than 5% excreted renally as glycerol and other metabolites. |
| Half-life | Triglycerides in Liposyn III 10% have a terminal elimination half-life of approximately 0.5 to 1 hour in patients with normal lipid metabolism. In neonates or hepatic impairment, half-life may be prolonged. |
| Protein binding | Free fatty acids are highly bound to albumin (>99%). Triglycerides are carried in chylomicron-like particles; no specific protein binding. |
| Volume of Distribution | Lipids are confined primarily to the intravascular space initially; Vd approximates plasma volume (0.04-0.05 L/kg). Free fatty acids distribute to tissues. |
| Bioavailability | Intravenous administration results in 100% bioavailability. |
| Onset of Action | When administered intravenously, elevation of serum triglycerides occurs within 15-30 minutes of infusion start. |
| Duration of Action | Serum triglyceride levels return to baseline within 2-4 hours after infusion cessation in patients with normal clearance. |
Intravenous infusion: 500 mL to 1000 mL per day, providing 10% lipid emulsion (100 g fat per liter), infused over 8-12 hours as part of parenteral nutrition, not to exceed 2.5 g fat/kg/day.
| Dosage form | INJECTABLE |
| Renal impairment | No specific dose adjustment for GFR; monitor serum triglycerides, electrolytes, and fluid status in renal impairment. Use with caution in severe renal failure due to risk of fluid overload and electrolyte imbalances. |
| Liver impairment | Child-Pugh Class A: No adjustment; Class B: Reduce dose by 25-50% and monitor triglycerides; Class C: Contraindicated or use extreme caution with dose reduction >50% and close monitoring of liver function and triglycerides. |
| Pediatric use | Intravenous: Initial dose 0.5-1 g fat/kg/day, increase by 0.5 g/kg/day to maximum 3 g fat/kg/day for term infants and 4 g fat/kg/day for preterm infants; administer over 20-24 hours continuously. |
| Geriatric use | No specific dose adjustment based on age alone; use standard adult dosing, but monitor for fluid overload, hypertriglyceridemia, and renal function due to age-related physiological changes. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for LIPOSYN III 10% (LIPOSYN III 10%).
| Breastfeeding | It is not known whether Liposyn III 10% is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when administered to a nursing woman. The M/P ratio is not available. |
| Teratogenic Risk | Liposyn III 10% is a lipid emulsion used as a source of calories and essential fatty acids. In pregnancy, there are no adequate and well-controlled studies. Animal reproductive studies have not been conducted. It is not known whether the drug can cause fetal harm when administered to a pregnant woman. As a component of total parenteral nutrition (TPN), it is used when oral nutrition is not possible. Fetal risks are likely related to the underlying maternal condition requiring TPN rather than the lipid emulsion itself. There is no specific evidence of teratogenicity; however, use during pregnancy only if clearly needed. |
■ FDA Black Box Warning
None.
| Serious Effects |
["Hypersensitivity to soybean oil, egg yolk phospholipids, or any component","Severe hyperlipidemia (e.g., lipemic serum, severe triglyceridemia)","Severe hepatic impairment","Severe coagulation disorders","Acute myocardial infarction or shock"]
| Precautions | ["Risk of fat overload syndrome (hypertriglyceridemia, fever, hepatomegaly, coagulopathy, thrombocytopenia) with rapid or high-dose infusion","Monitor serum triglycerides regularly; avoid infusion if significant hyperlipidemia","Risk of infection due to catheter-related bloodstream infections","Caution in patients with severe hepatic impairment, renal failure, or pancreatitis","May cause hypertriglyceridemia; monitor for signs of pancreatitis"] |
Loading safety data…
| Fetal Monitoring | Monitor for signs of fat overload syndrome (hepatomegaly, splenomegaly, thrombocytopenia, coagulopathy, hypertriglyceridemia) in the mother. In pregnancy, monitor maternal triglycerides, liver function tests, and coagulation parameters. Monitor fetal growth and well-being via ultrasound and non-stress tests as clinically indicated due to maternal underlying condition. |
| Fertility Effects | Animal studies have not been conducted to evaluate the effect on fertility. There is no known impact on human fertility from lipid emulsions. However, the underlying condition requiring TPN may affect fertility. |